CV Sciences, Inc. (CVSI) stock
CVSIOTCPharmaceutical PreparationsFiscal year ends December 31
$0.01−0.00 (-21.13%)
Close on Oct 19, 2026Market cap $2.53MP/E –Yield –
CV Sciences ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
CV Sciences's ebitda for the twelve months ending Sep 30, 2026 was -$228.00K. For fiscal 2025 it was -$278.00K. The highest annual figure on record is $10.77M in fiscal 2018.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$278.00K | – |
| FY2024 | Dec 31, 2024 | -$1.86M | -151.6% |
| FY2023 | Dec 31, 2023 | $3.60M | – |
| FY2022 | Dec 31, 2022 | -$5.86M | – |
| FY2021 | Dec 31, 2021 | -$17.29M | – |
| FY2020 | Dec 31, 2020 | -$21.72M | – |
| FY2019 | Dec 31, 2019 | -$16.52M | -253.5% |
| FY2018 | Dec 31, 2018 | $10.77M | – |
| FY2017 | Dec 31, 2017 | -$4.68M | – |
| FY2016 | Dec 31, 2016 | -$12.02M | – |
| FY2015 | Dec 31, 2015 | -$10.20M | – |
| FY2014 | Dec 31, 2014 | -$7.62M | – |
| FY2013 | Dec 31, 2013 | -$850.08K | – |
| FY2012 | Dec 31, 2012 | -$43.02K | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $400.00K | – |
| Q2 FY2026 | Jun 30, 2026 | -$279.00K | – |
| Q1 FY2026 | Mar 31, 2026 | -$295.00K | -417.2% |
| Q4 FY2025 | Dec 31, 2025 | -$54.00K | – |
| Q3 FY2025 | Sep 30, 2025 | -$244.00K | – |
| Q2 FY2025 | Jun 30, 2025 | -$73.00K | – |
| Q1 FY2025 | Mar 31, 2025 | $93.00K | – |
| Q4 FY2024 | Dec 31, 2024 | -$532.00K | – |
| Q3 FY2024 | Sep 30, 2024 | -$260.00K | – |
| Q2 FY2024 | Jun 30, 2024 | -$507.00K | – |
| Q1 FY2024 | Mar 31, 2024 | -$557.00K | -109.6% |
| Q4 FY2023 | Dec 31, 2023 | -$830.00K | – |
| Q3 FY2023 | Sep 30, 2023 | -$379.00K | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.02M | – |
| Q1 FY2023 | Mar 31, 2023 | $5.82M | – |
| Q4 FY2022 | Dec 31, 2022 | -$2.06M | – |
| Q3 FY2022 | Sep 30, 2022 | -$829.00K | – |
| Q2 FY2022 | Jun 30, 2022 | -$1.97M | – |
| Q1 FY2022 | Mar 31, 2022 | -$998.00K | – |
| Q4 FY2021 | Dec 31, 2021 | -$8.44M | – |
| Q3 FY2021 | Sep 30, 2021 | -$2.64M | – |
| Q2 FY2021 | Jun 30, 2021 | -$3.31M | – |
| Q1 FY2021 | Mar 31, 2021 | -$2.91M | – |
| Q4 FY2020 | Dec 31, 2020 | -$9.22M | – |
| Q3 FY2020 | Sep 30, 2020 | -$2.91M | – |
| Q2 FY2020 | Jun 30, 2020 | -$4.45M | -411.2% |
| Q1 FY2020 | Mar 31, 2020 | -$5.14M | – |
| Q4 FY2019 | Dec 31, 2019 | -$7.16M | -346.9% |
| Q3 FY2019 | Sep 30, 2019 | -$1.59M | -143.6% |
| Q2 FY2019 | Jun 30, 2019 | $1.43M | -58.2% |
| Q1 FY2019 | Mar 31, 2019 | -$9.20M | -1269.1% |
| Q4 FY2018 | Dec 31, 2018 | $2.90M | +1566.8% |
| Q3 FY2018 | Sep 30, 2018 | $3.66M | – |
| Q2 FY2018 | Jun 30, 2018 | $3.42M | – |
| Q1 FY2018 | Mar 31, 2018 | $787.00K | – |
| Q4 FY2017 | Dec 31, 2017 | $173.98K | – |
| Q3 FY2017 | Sep 30, 2017 | -$442.03K | – |
| Q2 FY2017 | Jun 30, 2017 | -$811.50K | – |
| Q1 FY2017 | Mar 31, 2017 | -$3.60M | – |
| Q4 FY2016 | Dec 31, 2016 | -$7.96M | – |
See a number that looks wrong?